Loading company…
YZY Biopharma Co., Ltd is a Wuhan company developing bispecific antibody drugs for tumors, immunity and inflammation.
YZY Biopharma develops bispecific antibody drugs, including M802 (HER2×CD3), M701 (EPCAM×CD3) and Y150, for diseases such as tumors, immunity, inflammation, cardiovascular conditions and infections. Established in 2010 and based in Wuhan, China, it is at the Series B stage. The company raised CNY 200 million in pre-series C funding in July 2022 and was listed on the Hong Kong Stock Exchange in September 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in